Business
Pfizer to develop mRNA vaccines without BioNTech
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Pfizer Inc (NYSE: PFE)‘s success in developing an effective COVID-19 vaccine in record time has given the pharmaceutical giant the confidence to invest heavily in the technology that underpins that vaccine. In an interview with The Wall Street Journal on Tuesday, CEO Albert Bourla revealed that Pfizer plans to become a leader in the development of new vaccines that rely on messenger RNA (mRNA).
Unfortunately for BioNTech (NASDAQ: BNTX), those plans don’t rely on a continuation of the collaboration agreement that brought the world its first authorized mRNA-based vaccine. According to Bourla, Pfizer doesn’t need to work with…
-
Noosa News20 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
Noosa News23 hours agoFrom Dreamy Dining Rooms to Moody Basement Bars, Nearly 200 Venues Have Been Shortlisted for the 2025 Australian Interior Design Awards
-
Noosa News21 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
Noosa News18 hours agoGyrocopter pilot injured in crash-landing on K’Gari, north of Brisbane